Personalized dosimetry assessment of [ <sup>177</sup> Lu]Lu-PSMA-617 radioligand therapy in the management of metastatic castration-resistant prostate cancer
This study indicates that the ADs of OARs and tumoral lesions from [<sup>177</sup>Lu]Lu-PSMA-617 RLT in patients with mCRPC are consistent with existing literature. The dosimetry findings suggest that increasing the administered activity of [<sup>177</sup>Lu]Lu-PSMA-617 RLT is feasible and does not pose a significant risk of adverse effects on OARs, as supported by our data. However, to validate the safety and efficacy of higher doses, further clinical follow-up studies are recommended.
Authors
- Elmira Yazdani (ORCID: https://orcid.org/0000-0001-8371-8832)
- Mahdi Sadeghi (ORCID: https://orcid.org/0000-0001-5055-4544)
- Najme Karamzade‐Ziarati (ORCID: https://orcid.org/0000-0002-0432-6193)
- Parham Geramifar (ORCID: https://orcid.org/0000-0002-7607-6859)
- Mahmood Kazemi-Jahromi
- Mahboobeh Asadi (ORCID: https://orcid.org/0000-0003-3451-6833)
Institutions
- Iran University of Medical Sciences (IR)
- Tehran University of Medical Sciences (IR)
Publication Details
- Journal
- International Journal of Radiation Biology
- Published
- 2024-09-20
- DOI
- https://doi.org/10.1080/09553002.2024.2404448
- Citations
- 5
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- Research Center for Infectious Diseases and Tropical Medicine, Tabriz University of Medical Sciences